ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 3121

Specific Antibody Subphenotypes in Rheumatoid Arthritis Are Associated with Unique HLA-DRB1 Residues at Position 11

Chikashi Terao1,2, Boel Brynedal3, Zuomei Chen4, Xia Jiang4, Helga Westerlind4, Monika Hansson5, Linda Mathsson-Alm6,7, Per Johan Jakobsson8, Karl Skriner9, Guy Serre10, Johan Rönnelid7, Leonid Padyukov8, Jane Worthington11, Lars Alfredsson4, Lars Klareskog8 and Soumya Raychaudhuri1,2,11, 1Departments of Genetics and Rheumatology, Brigham and Women'’s Hospital, Harvard Medical School, Boston, MA, 2Program in Medical and Population Genetics, Broad Institute, Boston, MA, 3Section of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Karolinska, Sweden, 4Section of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 5Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden, 6Thermo Fisher Scientific, Uppsala, Sweden, 7Department of Immunology Genetics and Pathology,Uppsala University, Uppsala, Sweden, 8Unit of Rheumatology, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, 9Humboldt University of Berlin, Berlin, Germany, 10Unité Différenciation Épidermique et Autoimmunité Rhumatoïde, Unité Mixte de Recherche, INSERM, Toulouse, France, 11Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: anti-citrullinated protein/peptide antibodies (ACPA), Genetic architecture, human leukocyte antigens (HLA) and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Wednesday, November 16, 2016

Title: Genetics, Genomics and Proteomics II

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose:   Antibody to citrullinated peptides/proteins (ACPA) is specific feature of rheumatoid arthritis (RA) and seen in 50 to 70% of RA patients. Amino acid (AA) position 11/13 in the HLA-DRβ1 is the strongest genetic risk factor in the HLA locus to ACPA(+) RA. We previously showed that HLA-DRB1 alleles interact to confer risk of ACPA(+) RA (Lenz et al Nat Gen 2015). However, genetic architectures underlying individual ACPA are still poorly understood. Here, we investigated the extent to which different individual ACPA are driven by distinct genetic factors within HLA locus.

Methods:   We phenotyped RA cases with a multiplex peptide array to quantify 18 fine-specific ACPA as well as 2nd generation cyclic ctrullinated peptide antibody (CCP2), the representative method to quantify ACPA. We queried 6,267 patients and 12,054 controls across 3 independent cohorts. We performed clustering and principal component analysis to identify subgroups of ACPAs. We imputed HLA genotypes and tested for MHC associations with specific ACPA with logistic regression models correcting for 10 principal components and cohort effects. We also evaluate interactive effects of combinations of HLA-DRB1 alleles on fine-specific ACPA(+) RA susceptibility to assess whether allelic interactions influence expression of specific ACPAs.

Results:  Clustering and principal component analysis of 18 fine ACPAs and CCP2 demonstrated that ACPAs could be classified into 2 distinct clusters, which we refer to as ACPA-A and ACPA-B. ACPA-A consisted of a total of 12 antibodies including CCP2 and an antibody recognizing a peptide derived from fibrinogen beta AA position 60 to 74 with positions 60, 72 and 74 citurillnated (Fibbeta60-74Ab) which was more strongly correlated with CCP2 than any other ACPA. ACPA-B contained a total of 7 antibodies including Fibbeta62-81cit72Ab, which reacts to a peptide sharing 12 AA sequences to the Fibbeta60-74Ab peptide but differs only in citrullination at one AA position. Position 11 of HLA-DRβ1 protein, which has six possible AA residues, showed the strongest associations in 14/18 ACPAs in intra-case analysis (omnibus p≤1.1×10-33). Intriguingly, Fibbeta62-81cit72Ab showed distinct association patterns of AA residues at the position 11 (p=1.1×10-50) from CCP2 associations. When we examined the subset of 175 case individuals that were positive for ACPA-B, but negative for all ACPA-A antibodies, we observed only weak evidence of association to position 11 (p=0.066), but did observe a significant association with HLA-B AA position 9 (p=1.2×10-7). We identified two novel allelic combinations specifically showing interactive effects on fine-specific ACPAs, for example DRB1*13:01 and 11:01 interact to influence expression of an antibody recognizing a peptide derived from heterogeneous ribonucleotide protein (p=3.1×10-4).

Conclusion:   These findings suggest that specific HLA-DRB1 alleles, and their interacting combinations lead to a different repertoire of antibodies, with reactivities to different citrullinated peptide sequences. They suggest that reactivity to multiple antigen sets might independently lead to RA.


Disclosure: C. Terao, Ab chips, 9; B. Brynedal, None; Z. Chen, None; X. Jiang, None; H. Westerlind, None; M. Hansson, None; L. Mathsson-Alm, Thermo Fisher Scientific, 3; P. J. Jakobsson, None; K. Skriner, None; G. Serre, anti-CCP assays, 7; J. Rönnelid, None; L. Padyukov, None; J. Worthington, None; L. Alfredsson, None; L. Klareskog, None; S. Raychaudhuri, None.

To cite this abstract in AMA style:

Terao C, Brynedal B, Chen Z, Jiang X, Westerlind H, Hansson M, Mathsson-Alm L, Jakobsson PJ, Skriner K, Serre G, Rönnelid J, Padyukov L, Worthington J, Alfredsson L, Klareskog L, Raychaudhuri S. Specific Antibody Subphenotypes in Rheumatoid Arthritis Are Associated with Unique HLA-DRB1 Residues at Position 11 [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/specific-antibody-subphenotypes-in-rheumatoid-arthritis-are-associated-with-unique-hla-drb1-residues-at-position-11/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/specific-antibody-subphenotypes-in-rheumatoid-arthritis-are-associated-with-unique-hla-drb1-residues-at-position-11/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology